Quo-Lab meets strict international quality targets – confirming it fit for purpose for diabetes testing The study aimed to evaluate the four POC HbA1c instruments according to Clinical and Laboratory ...

Diabetes Mellitus has become a worldwide epidemic, affecting approximately 425 million people. Unfortunately, one in two patients remains undiagnosed. HbA1c can play a major role in finding these ...

EKF Diagnostics, the global in vitro diagnostics company, announces that a recent study has confirmed that its Quo-Test® A1c point-of-care testing (POCT) analyzer shows comparable performance to a lab ...

Diabetes represents a serious global epidemic. Diabetes causes its own direct adverse effects but also predisposes patients to the development of both cardiovascular disease (CVD) and chronic kidney ...

Novel approach analyzes thousands of red blood cells from a small sample, showcasing the long-term potential of microfluidics for testing across conditions Using advanced microfluidic technology, our ...

EKF Diagnostics has announced that in a newly published paper [1] its Quo-Test® point-of-care (POC) hemoglobin A1c (HbA1c) analyzer has again been confirmed to meet International Federation of ...

In recognition of Diabetes Awareness Month, the American Red Cross will offer blood donors free HbA1c testing this November.

The complications related to poor blood sugar control and diabetes are significant, so identifying its presence and prompt treatment with lifestyle changes – and, if necessary, medications – is key.

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hhg4s5/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c ...